1044800

苯磺酸阿曲库铵

United States Pharmacopeia (USP) Reference Standard

• 别名: 2,2′-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium]dibenzenesulfonate, BW-33A, Tracrium
• 经验公式（希尔记法）: C₆₅H₈₂N₂O₁₈S₂
• CAS号: 64228-81-5
• 分子量: 1243.48
• MDL號碼: MFCD00797403
• 分類程式碼代碼: 41116107
• PubChem物質ID: 329749081
• NACRES: NA.24

属性

• 等級: pharmaceutical primary standard
• API 家族: atracurium
• 製造商／商標名: USP
• 應用: pharmaceutical (small molecule)
• 格式: neat
• 儲存溫度: 2-8°C
• SMILES 字串: [O-]S(=O)(=O)c1ccccc1.[O-]S(=O)(=O)c2ccccc2.COc3ccc(CC4c5cc(OC)c(OC)cc5CC[N+]4(C)CCC(=O)OCCCCCOC(=O)CC[N+]6(C)CCc7cc(OC)c(OC)cc7C6Cc8ccc(OC)c(OC)c8)cc3OC
• InChI: 1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2
• InChI 密鑰: XXZSQOVSEBAPGS-UHFFFAOYSA-L
• 基因資訊: human ... CHRNA1(1134) , CHRNB1(1140) , CHRND(1144) , CHRNE(1145) , CHRNG(1146)

说明

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

• The feasibility of the posterior tibial nerve-flexor hallucis brevis pathway applied in neuromuscular monitoring: This multicentric, controlled, and prospective clinical trial investigates a new method for neuromuscular monitoring using Atracurium besylate, providing insights into improving surgical anesthesia practices (Chen et al., 2024).


• Onset and duration of action of escalating doses of atracurium in anesthetized healthy goats: This study assesses the pharmacokinetics and pharmacodynamics of Atracurium besylate in veterinary medicine, highlighting its efficacy and safety in non-human subjects, which is crucial for translating findings to human clinical settings (Ishihara et al., 2024).


• Under-dosing and over-dosing of neuromuscular blocking drugs and reversal agents: beware of the risks: This editorial discusses the critical balance required in dosing Atracurium besylate to optimize patient outcomes and minimize side effects in surgical settings, emphasizing the importance of precise dosing for effective neuromuscular blockade (Hunter and Blobner, 2024).


• Comparison of the Onset of Action, Maintenance, and Recovery of Three Weight-based Dosing of Cisatracurium in Patients with Morbid Obesity in Laparoscopic Bariatric Surgery: Although focused on Cisatracurium, this study provides comparative insights that could be applicable to similar studies on Atracurium besylate, particularly in terms of dose adjustment for specific patient populations undergoing surgical procedures (Rokhtabnak et al., 2023).


• Neuromuscular Blockade: This piece provides a broad overview of neuromuscular blocking agents like Atracurium besylate, discussing their mechanisms and applications in clinical anesthesia, which is essential for understanding the full scope of these drugs′ utility in medical practice (Cook and Simons, 2024).

生化／生理作用

Nicotinic acetylcholine receptor antagonist.

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable